Hasil Pencarian - Jianying Zhou, MD

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

    Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC oleh Yi-Long Wu, MD, Shun Lu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jianying Zhou, MD, Takashi Seto, MD, Myung-Ju Ahn, MD, PhD, Wu-Chou Su, MD, Noboru Yamamoto, MD, PhD, Dong-Wan Kim, MD, PhD, Jolanda Paolini, MSc, Tiziana Usari, BSc, Laura Iadeluca, PhD, Keith D. Wilner, PhD, Koichi Goto, MD, PhD

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407

    Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407 oleh Ying Cheng, MD, Li Zhang, MD, Jie Hu, MD, PhD, FCCP, Donglin Wang, MD, ChengPing Hu, MD, Jianying Zhou, MD, Lin Wu, MD, Lejie Cao, MD, Jiwei Liu, MD, Helong Zhang, MD, Hong Sun, MD, Ziping Wang, PhD, Hongjun Gao, MD, Yuping Sun, MD, Ben Li, PhD, Xiaohan Hu, PhD, MPH, Paul Schwarzenberger, MD, Luis Paz-Ares, MD, PhD

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study

    Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study oleh Caicun Zhou, MD, PhD, You Lu, MD, Sang-We Kim, MD, PhD, Thanyanan Reungwetwattana, MD, Jianying Zhou, MD, Yiping Zhang, MD, Jianxing He, MD, PhD, Jin-Ji Yang, MD, Ying Cheng, MD, Se-Hoon Lee, MD, PhD, Jianhua Chang, MD, Jian Fang, MD, Zhe Liu, PhD, Lilian Bu, MSc, Li Qian, MD, Tingting Xu, MD, Venice Archer, MB ChB, MSc, Magalie Hilton, MSc, Mingzhu Zhou, MSc, Li Zhang, MD

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations

    Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations oleh Shun Lu, MD, Jian Fang, MD, Xingya Li, MD, Lejie Cao, MD, Jianying Zhou, MD, Qisen Guo, MD, Zongan Liang, MD, Ying Cheng, MD, Liyan Jiang, MD, Nong Yang, MD, Zhigang Han, MD, Jianhua Shi, MD, Yuan Chen, MD, Hua Xu, MD, Helong Zhang, MD, Gongyan Chen, MD, Rui Ma, MD, Sanyuan Sun, MD, Yun Fan, MD, Songhua Fan, MD, Jie Yu, MD, Puhan Lu, PhD, Xian Luo, MS, Weiguo Su, PhD

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

    Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC oleh Qing Zhou, MD, PhD, Ross A. Soo, MBBS, PhD, Gee-Chen Chang, MD, PhD, Chao-Hua Chiu, MD, Hidetoshi Hayashi, MD, PhD, Sang-We Kim, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Jianying Zhou, MD, Victor Ho-Fun Lee, MD, Dong-Wan Kim, MD, PhD, Baohui Han, MD, PhD, James Chung Man Ho, MD, FRCP, Chia-Chi Lin, MD, PhD, Shun Lu, MD, Anna Polli, BS, Anna Maria Calella, PhD, Jean-François Martini, PhD, Chew Hooi Wong, PhD, Tony Mok, MD, Hye Ryun Kim, MD, PhD, Yi-Long Wu, MD

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: